<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672253</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T re-treatment-MM</org_study_id>
    <nct_id>NCT03672253</nct_id>
  </id_info>
  <brief_title>CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma</brief_title>
  <official_title>Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, single-center, phase 1 study, to determine the safety and&#xD;
      efficacy of autologous reinfusion of CAR-T cells targeting BCMA in the treatment of&#xD;
      refractory/relapsed multiple myeloma (r/r MM) who get recurrence and progression after&#xD;
      previous CAR-T cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events</measure>
    <time_frame>Day 1-30 days after injection</time_frame>
    <description>assessed by CTCAE v4.0, &gt;= Grade 1 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-myeloma responses</measure>
    <time_frame>Day 1-60 months</time_frame>
    <description>by measuring the changes of aberrant immunoglobulin in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-myeloma responses</measure>
    <time_frame>Day 1-60 months</time_frame>
    <description>multiple myeloma cells in bone marrow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma Progression</condition>
  <arm_group>
    <arm_group_label>CAR-T Re-treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR-T Re-treatment</intervention_name>
    <description>Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.</description>
    <arm_group_label>CAR-T Re-treatment group</arm_group_label>
    <other_name>CAR-T Re-treatment for r/r MM targeting BCMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a confirmed prior diagnosis of active multiple myeloma as defined&#xD;
             by the updated IMWG criteria.&#xD;
&#xD;
          2. Patients with refractory multiple myeloma. Clear BCMA expression must be detected on&#xD;
             malignant plasma cells from either bone marrow or a plasmacytoma by flow cytometry or&#xD;
             immunohistochemistry.&#xD;
&#xD;
          3. Refractory diseaseï¼š1) At least 3 prior regimens, which must at least have contained&#xD;
             bortezomi. or 2) other circumstances identified by clinical doctors.&#xD;
&#xD;
          4. Relapse criteria in NCCN clinical practice guidelines in Oncology: Multiple Myeloma&#xD;
             (2016.V2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child-bearing potential or who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Have any active and uncontrolled infection: hepatitis B, hepatitis C, HIV, or other&#xD;
             fatal viral and bacterial infection.&#xD;
&#xD;
          3. Systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or&#xD;
             equivalent dose of another corticosteroid are not allowed within 2 weeks prior to&#xD;
             either the required leukapheresis or the initiation of the conditioning chemotherapy&#xD;
             regimen.&#xD;
&#xD;
          4. Patients with any uncontrolled intercurrent illness or serious uncontrolled medical&#xD;
             disorder.&#xD;
&#xD;
          5. Patients with CNS metastases or symptomatic CNS involvement (including cranial&#xD;
             neuropathies or mass lesions and spinal cord compression).&#xD;
&#xD;
          6. History of allogeneic stem cell transplantation. Have active acute or chronic&#xD;
             graft-versus-host-disease (GVHD), or require immunosuppressant medications for GVHD,&#xD;
             within 6 months of enrollment.&#xD;
&#xD;
          7. Patients with active autoimmune skin diseases such as psoriasis or other active&#xD;
             autoimmune diseases such as rheumatoid arthritis.&#xD;
&#xD;
          8. other conditions that excluded by clinicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan-Hong Zhao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

